Ascenta Therapeutics (Michigan) and The Leukemia & Lymphoma Society Announce Agreement to Develop AT-406 for Leukemia (12/6/2010)

Ascenta Therapeutics is a biopharmaceutical company that develops medicines for cancer treatment. The company was co-founded by Dr. Marc Lippman of the University of Miami (and previously at the University of Michigan), Dr. Shaomeng Wang of the University of Michigan, and Dr. Dajun Yang.

From the copmany’s press release:
Ascenta Therapeutics, Inc. and The Leukemia & Lymphoma Society (LLS) today entered into an agreement whereby the LLS will support clinical development of Ascenta’s oral small molecule inhibitor of IAPs (inhibitor of apoptosis proteins), AT-406, for patients with acute myeloid leukemia (AML). read full press release

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s


%d bloggers like this: